How should brittle diabetes be managed in a patient using an insulin pump?

Management of Brittle Diabetes with Insulin Pump Therapy

Insulin pump therapy (continuous subcutaneous insulin infusion, CSII) should be initiated or continued in patients with brittle diabetes, as it significantly improves metabolic control, reduces severe glycemic excursions, and decreases hospitalization rates compared to multiple daily injections. 1, 2

Core Management Strategy

Initial Assessment and Optimization

Before relying solely on pump therapy, you must systematically exclude and address reversible causes of brittleness:

• Rule out organic causes: delayed gastric emptying from autonomic neuropathy, malabsorption disorders, defective insulin absorption sites (lipohypertrophy), and medications affecting glucose metabolism (alcohol, antipsychotics) 3
• Assess psychosocial factors: factitious insulin omission, eating disorders (especially bulimia in young women), depression, and medication non-adherence 4
• Identify life-stage specific issues: In elderly patients, look for frailty, chronic renal failure, dementia, vision loss, loss of counterregulation, and unintentional insulin dosing errors 4, 2

Pump Therapy Implementation

The pump should deliver only rapid-acting insulin analogues (Novorapid, Humalog, or Apidra) with highly individualized basal and bolus programming 5:

Basal Rate Optimization

• Perform a formal "basal test" before surgery or during stable periods: measure glucose every 3 hours during fasting, with acceptable variation of ≤1.7 mmol/L (≤30 mg/dL) 5
• Program multiple basal rates throughout the 24-hour period to match physiologic insulin needs
• Adjust rates every 3-6 months based on weight changes, exercise patterns, and menstrual cycles 5

Bolus Dosing

• Use the pump's on-board calculator with individualized insulin-to-carbohydrate ratios (e.g., 1:10 means 1 unit per 10g carbohydrate) 5
• Program insulin sensitivity factors (e.g., 1:3 ratio means 1 unit lowers glucose by 3 mmol/L) 5
• Enable "insulin-on-board" tracking to prevent stacking and hypoglycemia 5

Critical Safety Measures

A major pitfall: pumps deliver only short-acting insulin, so disconnection or occlusion causes relative insulin deficiency within 1 hour and absolute deficiency within 4 hours, with severe risk of ketoacidosis 5:

• Change infusion sets every 2-3 days to prevent absorption problems 5
• Use plastic (not metal) cannulas if diathermy is anticipated 5
• Check two capillary glucose readings several hours apart after each set change 5
• Monitor for hyperglycemia >16.5 mmol/L (>3 g/L) and check for ketosis immediately 6

Enhanced Monitoring

Integrate continuous glucose monitoring (CGM) with the pump whenever possible, as this combination provides superior glycemic control in brittle diabetes 1:

• CGM allows real-time detection of glycemic excursions before they become severe
• Automated insulin delivery (AID) systems that adjust basal rates based on CGM data are now the preferred option 7
• For patients without AID access, sensor-augmented pumps with low-glucose suspend features reduce hypoglycemia risk 7

When Patients Cannot Self-Manage

If the patient loses capacity to manage the pump (delirium, altered consciousness, severe illness), immediately switch to intravenous insulin infusion or subcutaneous basal-bolus regimen 5, 6:

• Do NOT leave the pump running unsupervised
• Give immediate subcutaneous long-acting insulin when disconnecting the pump 6
• Resume pump only when patient regains full autonomous management capability 6

Alternative Routes for Refractory Cases

For the most severely brittle patients who fail standard subcutaneous pump therapy:

• Intraperitoneal insulin delivery via implantable pumps showed sustained improvement (HbA1c from 15.2% to 9.2%) in patients unresponsive to subcutaneous routes 8, 9
• Consider islet transplantation for patients with hypoglycemic unawareness, BMI <25, and normal renal function 3

Expected Outcomes

With properly implemented pump therapy, expect:

• HbA1c reduction of 1.4% within 6 months 1
• Elimination or marked reduction in hospitalizations 1, 2
• Mean blood glucose improvement from 237 mg/dL to 126 mg/dL 9
• Improved quality of life and lifestyle flexibility 1

Common Pitfalls to Avoid

1. Don't assume psychological causes first: In elderly patients especially, brittleness often results from altered biology, not psychiatric issues 2
2. Don't use standard basal-bolus pump programming: Some extremely brittle patients require modified regimens with variable square-wave infusions and no boluses 10
3. Don't continue pump therapy during incapacity: This leads to dangerous ketoacidosis 5
4. Don't forget lipohypertrophy: Rotate injection sites meticulously as this distorts insulin absorption 11